CHICAGO (Reuters) – An implantable microchip delivered osteoporosis medicine to a small group of Danish women, raising hope for a new kind of drug-delivery device that might allow patients to skip regular injections, researchers said.

The device, now being developed by privately held Microchips Inc, releases the drug in response to an electrical signal.

“Until now, you never had any way you could do this,” said Dr. Robert Langer of the Massachusetts Institutes of Technology, who helped to develop the technology and is a board member of Microchips Inc.

Langer said the device could be used for different types of injectable drugs where getting people to take their medications regularly is a problem.

That is often the case in patients with severe osteoporosis, who tend to skip doses of their medications because they cannot tell whether or not the injections are affecting the density of their bones.

That is something the microchip was designed to overcome, said Robert Farra of Massachusetts-based Microchips, which paid for the study. Farra, Langer and colleagues published a paper on the study in Science Translational Medicine.

Instead of constantly releasing small amounts of drug, like most drug-delivery systems, the microchip releases medication on command all at once, much like an injection would.

MELTING METAL

The microchip itself is a thin wafer, about the size of a small coin, made with tiny wells that hold concentrated doses of medication. These doses are covered with a thin platinum/titanium film, which melts when exposed to a electrical signal that can be preprogrammed or controlled wirelessly. The wafer is implanted under the skin in the abdomen in a device that is roughly the size of a heart pacemaker, Langer said.

In the system's first test in people, the team implanted the device in eight Danish women aged 65 to 70 with a severe form of osteoporosis which required injections of Eli Lilly & Co's hormone treatment teriparatide.

The researchers sent daily signals to the microchip device to release the drug for up to 20 doses. Then, they followed up with a period in which the women took hormone injections.

As seen in animal studies, a fibrous collagen-based membrane developed around the device, but the drug still performed just as well as daily injections in the women, improving bone formation and reducing the risk of fractures, the researchers said.

Still, there were some hitches.

John Watson, a professor of bioengineering at the University of California, San Diego, said in an editorial the device failed to work in one of the patients, and that data was not included in the analysis.

And the team had some manufacturing issues and was able to manufacture only one device with all 20 reservoirs filled with the study drug. Even so, all doses in the microchips were released in the patients, a sign that the device could work in people, Watson said.

“Several years are still needed to bring this technology to approval by the U.S. Food and Drug Administration and to the clinical promise reflected in this small study,” Watson wrote.

The current device holds only 20 doses, but Langer said the group is working on adding more doses to the device.

The company hopes to have a version of the device on the market in five years. Langer said he sees potential for other uses, such as treating diabetes or delivering cancer drugs.

(Editing by Mohammad Zargham)

(This changes February 16 story in paragraphs two and eight to show drug is released by melting a platinum/titanium film, not a gold film)

Follow this link:
Microchip device delivers drug

Implanted microchip that releases medications on command tested in people

Web edition : Thursday, February 16th, 2012

VANCOUVER — An implanted microchip that releases medication on command from wireless signals has been demonstrated in people for the first time using a drug for osteoporosis.

This tiny device, implanted under the skin, could be useful in treating many diseases that require taking medication regularly, scientists reported February 16 at the annual meeting of the American Association for the Advancement of Science.

“This opens up profound possibilities for improving the treatment of patients and the potential of telemedicine,” said Robert Farra, president of MicroCHIPS Inc., the company that funded and conducted part of the study. A paper describing the results was also published online February 16 in Science Translational Medicine by collaborators from MicroCHIPS, MIT, Harvard and Case Western University.

The idea behind a microchip that could release chemicals in the body at precise times was first developed by MIT scientists over a decade ago. But researchers needed to make sure that medications were well stored in the device. Also, the immune system tends to create a barrier of collagen around implanted devices, which could make it difficult for the drug to make it into the bloodstream.

In the new study, a device with individual doses of the drug teriparatide sealed inside was implanted under the waistline in eight women with osteoporosis. When the device’s microprocessor receives a wireless signal, a current runs through the microchip, breaking open the metal layers that contain a single dose of the drug.

About two months after the device was implanted — and after the immune system’s protective barrier had formed — wireless signals programmed the device to release daily doses of teriparatide. The drug, which increases bone mass, is usually given by injection.

Based on blood tests, the doses from the device appeared to bump up levels of a molecule called P1NP, which indicates bone building — evidence that teriparatide released from the microchip works as it should.

Still, there are technical limitations with this device. James Watson, a researcher in Bioengineering at University of California, San Diego, said that the consistency of the devices is a concern. One device didn’t release any medication in one of the original patients.

No side effects appeared in any of the study participants, Farra said. What’s more, many patients said they weren’t bothered by the device or had, in fact, forgotten about it.

Found in: Biomedicine and Body & Brain

Read this article:
Osteoporosis drugs delivered wirelessly

CHICAGO (Reuters) – An implantable, wireless microchip delivered osteoporosis medicine to a small group of Danish women, raising hope for a new kind of drug delivery device that might allow patients to skip regular injections, U.S. researchers said on Thursday.

The device, now being developed by privately held Microchips Inc, has a wireless receiver that signals the microchip to release the drug.

“Until now, you never had any way you could do this,” said Dr. Robert Langer of the Massachusetts Institutes of Technology, who helped to develop the technology and is a board member of Microchips Inc.

Langer said the device could be used for different types of injectable drugs where getting people to take their medications regularly is a problem.

That is often the case in patients with severe osteoporosis, who tend to skip doses of their medications because they cannot tell whether or not the injections are affecting the density of their bones.

That is something the microchip was designed to overcome, said Robert Farra of Massachusetts-based Microchips, which paid for the study. Farra, Langer and colleagues published a paper on the study in Science Translational Medicine.

Instead of constantly releasing small amounts of drug, like most drug-delivery systems, the microchip releases medication on command all at once, much like an injection would.

It can be activated by telephone or computer using a special radiofrequency reserved for medical use to safeguard against accidental release of the drug, Langer said.

GOLD NANOPARTICLES

The microchip itself is a thin wafer, about the size of a small coin, made with tiny wells that hold concentrated doses of medication. These doses are covered with a layer of gold nanoparticles, which dissolve when exposed to a certain radiofrequency. The wafer is implanted under the skin with a receiver device that is roughly the size of a heart pacemaker, Langer said.

In the system's first test in people, the team implanted the device in eight Danish women aged 65 to 70 with a severe form of osteoporosis which required injections of Eli Lilly & Co's hormone treatment teriparatide.

The researchers sent daily signals to the microchip device to release the drug for up to 20 doses. Then, they followed up with a period in which the women took hormone injections.

As seen in animal studies, a fibrous collagen-based membrane developed around the device, but the drug still performed just as well as daily injections in the women, improving bone formation and reducing the risk of fractures, the researchers said.

Still, there were some hitches.

John Watson, a professor of bioengineering at the University of California, San Diego, said in an editorial the device failed to work in one of the patients, and that data was not included in the analysis.

And the team had some manufacturing issues and was able to manufacture only one device with all 20 reservoirs filled with the study drug. Even so, all doses in the microchips were released in the patients, a sign that the device could work in people, Watson said.

“Several years are still needed to bring this technology to approval by the U.S. Food and Drug Administration and to the clinical promise reflected in this small study,” Watson wrote.

The current device holds only 20 doses, but Langer said the group is working on adding more doses to the device.

The company hopes to have a version of the device on the market in five years. Langer said he sees potential for other uses, such as treating diabetes or delivering cancer drugs.

SOURCE: http://bit.ly/xUUOwu Science Translational Medicine, February 16, 2012.

Read the original post:
Microchip delivers drug; can it replace shots?

Public release date: 17-Feb-2012
[ | E-mail | Share ]

Contact: Lindsay Brooke
Lindsay.brooke@nottingham.ac.uk
44-011-595-15751
University of Nottingham

The University of Nottingham spin-out company, Critical Pharmaceuticals, has announced a ?545,000 collaboration with the University to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone each year, at a cost of around ?2 billion to the NHS.

Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. The consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.

The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare.

Critical Pharmaceuticals CriticalSorb? nanotechnology is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $100 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb? has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients. Critical Pharmaceuticals lead product is a nasal formulation of human growth hormone (CP024) that uses CriticalSorb? and is currently in phase 1 clinical development.

Critical Pharmaceuticals is an emerging biotechnology company. CEO, Dr Gareth King, said: “We are excited about working with internationally-recognised clinicians and scientists at The University of Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative formulation of teriparatide and look forward to the day we can offer it as an attractive alternative to daily injection for the many older people living with osteoporosis”.

The University of Nottingham has world-leading capabilities in clinical and basic research in osteoporosis, geriatric care, bone pathophysiology and medical imaging. The use of University expertise for imaging drug deposition and clearance will greatly enhance the development of this formulation. This project will draw on interdisciplinary collaborative research from international experts Dr Richard Pearson (Division of Orthopaedic & Accident Surgery), Professor Alan Perkins (Division of Radiological and Imaging Sciences) and Professor Tahir Masud (Geriatric Medicine).

Dr Richard Pearson, Senior Research Fellow in The University of Nottingham's Faculty of Medicine and Health Sciences, said “I'm delighted to collaborate on this project that will enable us to further develop the world-leading research and development capability at The University of Nottingham for the evaluation of drugs for osteoporosis and to work closely with Critical Pharmaceuticals scientists on the development of an exciting new therapy for this debilitating disease”.

###

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Originally posted here:
Nano-enabled nasal spray for osteoporosis

Osteoporosis medication via remote-control instead of a shot? Scientists implanted microchips in seven women that did just that, oozing out the right dose of a bone-strengthening drug once a day without them even noticing.

Implanted medicine is a hot field, aiming to help patients better stick to their meds and to deliver those drugs straight to the body part that needs them.

But Thursday's study is believed the first attempt at using a wirelessly controlled drug chip in people. If this early-stage testing eventually pans out, the idea is that doctors one day might program dose changes from afar with the push of a button, or time them for when the patient is sleeping to minimize side effects.

The implant initially is being studied to treat severe bone-thinning osteoporosis. But it could be filled with other types of medication, said co-inventor Robert Langer of the Massachusetts Institute of Technology.

“It's like `Star Trek,'” said Langer, who co-authored the study appearing Thursday in the journal Science Translational Medicine. “Just send a signal over a special radio wave, and out comes the drug.”

Today's medication implants continuously emit their drugs until they run dry. One example is a dime-sized wafer that oozes chemotherapy directly onto the site of a surgically removed brain tumor, targeting any remaining cancer cells. Another is a contraceptive rod that is implanted in the arm and releases hormones to prevent pregnancy.

A next step would be more sophisticated implants that release one dose at a time, programmable to skip or add a dose as needed, said biomedical engineer Ellis Meng of the University of Southern California. Meng wasn't involved with the MIT study but also is developing this kind of technology, and called Thursday's report “an important milestone.” Women with severe osteoporosis sometimes are prescribed daily injections of the bone-building drug teriparatide, known by the brand Forteo. But many quit taking it because of the hassle of the shots. In the study, the microchip held doses of that drug inside tiny wells that are sealed shut with a nano-thin layer of gold. Sending a wireless signal causes the gold on an individual well to dissolve, allowing that dose to diffuse into the bloodstream, Langer explained. In a doctor's-office procedure, the microchip was implanted just below the waistline into eight women with osteoporosis in Denmark. Testing found one microchip wasn't responding to the signals. The other seven women had their implants programmed to automatically emit a once-a-day dose beginning eight weeks later. The chips could have begun working right away, said Robert Farra, CEO of MicroCHIPS Inc., a Massachusetts company that has licensed the device and funded the study. But animal research showed a scar tissue-like membrane forms around the pacemaker-sized implant. So he waited until that blockage formed to signal the first of 20 once-a-day doses to begin, to see if the drug could get through.

Blood testing showed the implant delivered the drug as effectively as the women's usual daily injections, and the device appeared to be safe, the researchers reported. It will take large-scale studies to prove the implant works as well as the long-used shots, cautioned osteoporosis specialist Dr. Ethel Siris of New York-Presbyterian Hospital/Columbia University. “They're a long way from proving that this mode of administration is going to work,” she said. But it's an intriguing idea because “it's daunting to have to take a daily shot.” Farra said his company hopes to begin a larger-scale test, using a chip that can hold 365 doses, in 2014. While doses of this osteoporosis medicine typically aren't adjusted, he said, the eventual goal is for patients to carry a cell phone-sized device that would provide wireless feedback to the doctor who programs their implants.

Source: Yellowbrix

Follow this link:
Osteoporosis Medication Delivered by Remote-Controlled Chip Implant

Public release date: 16-Feb-2012
[ | E-mail | Share ]

Contact: Natasha Pinol
npinol@aaas.org
202-326-7088
American Association for the Advancement of Science

Osteoporosis patients could soon ditch daily injection pens for an implantable microchip that releases medication at the push of a remote-controlled button, reports a new study appearing 16 February 2012 in the journal Science Translational Medicine.

The clinical trial, composed of a group of women with osteoporosis in Denmark, is the first to test a wirelessly controlled microchip capable of releasing drugs into the body at any time.

?Patients will be freed from having to remember to take their medication and don?t have to experience the pain of multiple injections,? said Robert Farra, President and Chief Operating Officer of MicroCHIPS, Inc., the Massachusetts-based company behind the device. Farra is a co-author of the study, along with colleagues from MIT, Harvard Medical School, OnDemand Therapeutics Inc and Case Western Reserve University.

Unlike most drug delivery devices, which release small amounts of drug slowly over time, the microchip releases medication on command from an external wireless device. This controlled system gets medicine into the bloodstream quickly, similar to an injection.

?Physicians will be able to seamlessly adjust their patients? therapy using a computer or cell phone,? said Farra.

The authors figure the microchip may be a more appealing and possibly cheaper alternative to long-term use of prefilled daily injection pens.

Patients with severe osteoporosis often have to give themselves daily injections of medication that requires refrigeration. Aside from the psychological burden of daily injections, older people may have arthritis or other problems that make injections physically difficult.

Moreover, since osteoporosis is a ?silent? disease ? affected individuals don?t feel better or worse as their bone density decreases ? many patients simply stop taking medication to avoid the hassle of daily injections.

The implant could help circumvent the high drop off in compliance and dramatically boost the quality of life for millions of osteoporosis patients. The device may also be useful for treating other chronic diseases like multiple sclerosis, heart disease or even cancer.

Roughly the size of a pacemaker, the device holds daily doses of a drug inside tiny wells that pop open either on a pre-programmed schedule or via a wireless signal.

?The drugs are in different wells. Each of these wells is covered by a nano-thin layer of gold which protects the drug for years if needed and prevents it from being released,? said Robert Langer, Professor at MIT and co-author of the Science Translational Medicine paper.

Sending a wireless signal to the well causes the gold to dissolve, freeing medication into the bloodstream.

Adapting microchip technology for human use is no small feat. The team first had to figure out a way to seal each reservoir airtight at room temperature. They developed a special compression welding process designed to provide a long-term seal. The researchers also developed the gold layer, which is strong enough to protect the contents of each reservoir, but thin enough to dissolve on command.

Despite the microchip?s proven ability to deliver drugs in the lab, once it was implanted into animals, a fibrous collagen-based membrane tended to develop around the device.

The researchers were concerned that this fibrous tissue could potentially slow down the absorption of medication, and one of the aims of this study was to determine if the membrane decreased effectiveness.

The researchers implanted the microchip just below the waistline, into seven women between the ages of 65 and 70. The procedure can be performed in a doctor's office with local anesthetic.

Tracking the women for 12 months, the team showed that the implant delivered the drug teriparatide just as effectively as daily injections, although the fibrous membrane did form around the device. Treatment improved bone formation and reduced the risk of bone fracture, as evidenced by the presence of biochemical markers signaling bone formation, bone mass and bone resorption.

?And there is much less variation from dose to dose than injections, so it's safer and more effective in that sense,? Langer said. The chip was removed from participants at the end of the one-year treatment.

The company hopes to make the device available for mainstream use in five years.

###

This study was funded by MicroCHIPS, Inc.

The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society, and publisher of the journal, Science (http://www.sciencemag.org) as well as Science Translational Medicine (http://www.sciencetranslationalmedicine.org) and Science Signaling (http://www.sciencesignaling.org). AAAS was founded in 1848, and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (http://www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert!, http://www.eurekalert.org, the premier science-news Web site, a service of AAAS.

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See original here:
Implantable microchip delivers medicine to women with osteoporosis

KIMS Qatar Medical Centre introduced its newly started Osteoporosis Management Clinic at a recent briefing.
The new clinic is set up under Dr Ashish Nathmadhav Bhangle, a specialist in orthopaedic surgery.
While making a presentation Dr Bhangle said he is focusing on conditions like osteomalacia (Vitamin D deficiency), osteoporosis, chronic degenerative diseases like osteoarthritis of knees and cervical and lumbar spondylosis which are very common in Qatar.
The most common symptoms of osteoporosis are overall muscle weakness, non-specific bone pain, easy fatigability, lethargy etc. “People suffering from osteoporosis may not even recall a trivial fall or trauma that might cause a fracture in the foot or spine. Spinal compression fractures may result in loss of height with a stooped posture (called dowager’s hump). Fractures at other sites, commonly the hip or bones of the wrist, usually result from a trivial fall,” pointed out Dr Bhangle.
Lebanese national Suzanne Adib Jurbi, the first patient treated at the Osteoporosis Management Clinic was also present. She hailed the treatment extended to her by the team led by Dr Bhangle.
At the briefing, besides KIMS Qatar executive director Nishad Azeem chief medical officer Dr K M R Mathew, and manager (marketing & business development) Abhik Roy also spoke.

Original post:
Presentation on osteoporosis

New data fill a gap in osteoporosis screening recommendations, suggesting that postmenopausal women undergo bone mineral density (BMD) testing yearly, every 5 years, or every 15 years based on their BMD T scores.

The study, published in January in the New England Journal of Medicine, followed up 4957 women aged 67 years or older for 15 years. The participants were part of the Study of Osteoporotic Fractures, which began in 1986 and is the longest running osteoporosis study in the United States. A previous analysis from this group showed that in healthy, older postmenopausal women, a repeat BMD test performed 8 years after the initial test didn't provide much new information in predicting fracture risk (Hillier TA et al. Arch Intern Med. 2007;167[2]:155-160).

In the newest analysis, women studied had normal BMD—a T score at the femoral neck and total hip of ?1.00 or higher—or osteopenia, which is …

Read the rest here:
Osteoporosis Screening May Be Needed Less Often Than Previously Believed [Medical News & Perspectives]

(MENAFN – Arab News) The first conference on osteoporosis, which concluded Thursday in Jeddah, called for the public to consult the Center of Excellence for Osteoporosis Research, a division of King Abdulaziz University in Jeddah, for free checkups for all age groups, with special attention to people above 45 years.

Osteoporosis is a medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of calcium or vitamin D.

The conference is part of the Prince Sultan National Osteoporosis Awareness Campaign, which will last for four years and will be completed in cooperation with the media as well as public and private hospitals and clinics, with a special focus on rural areas.

Specialists highlighted the need for more awareness among the public to increase the consumption of calcium and getting exposed to the sun, since both a lack of calcium and vitamin D are highly linked to osteoporosis.

A sum of SR100 million have been allocated to this campaign in the hope that more individuals will head to hospitals at early stages, when the illness can still be cured. The campaign will organize three more conferences in the coming years, in which it will cooperate with different American, European and Arab universities. These conferences will also follow up on the implementation of previous recommendations.

According to researches conducted at the Center of Excellence for Osteoporosis Research, there will be 900,000 cases of osteoporosis in the Kingdom by 2030.

Head of the center Mohammad Al-Aradawi said that treating these cases would cost SR30 billion.

The campaign depends on donations from the private sector and hopes to highlight the threat of this disease.

Thirty-two percent of men above 50 are at risk for this disease, while this percentage can go as high as 44.5 among women, said Osama Taib, rector of King Abdulaziz University.

“We cannot but combat this illness by all means and through awareness campaigns that target all layers of the society,” he added.

Excerpt from:
Saudi- Conference calls for osteoporosis screening

Osteoporosis is a bone disease that is affects many Filipinos. Beware, that muscle pain that's been bothering you could be the beginnings of osteoporosis.

Some individuals feel the manifestation of pain but majority of those afflicted by osteoporosis hardly feel a thing. Everything feels normal but something is already wrong. This is why osteoporosis is often called the silent disease.

Lene Almoniña and her sister Mary Ann Suzon found out that they are at risk of osteoporosis after having a bone scan analysis conducted by Anlene. Lene, 50, married and with two children, was not aware of her bone condition. Lene's mind was on more pressing matters like running her business.

“Last year, I saw the Anlene Bone Scan booth in a mall and thought I’d have myself checked. It was when I found out that I was in moderate risk of osteoporosis,” Lene recalled.

Mary Ann, on the other hand, already felt pain on her left knee that ran up to her back. She found it difficult to walk at times. Mary Ann, 48 and the mother of four, would commute to work but, lately, would ask her husband to give her a ride because of the pain. When she went to the Anlene Bone Scan activity held in a mall, she learned that she was already under the high risk category.

Mary Ann was alarmed that she might not be able to go to work anymore. It was at this point that she decided to do something about her condition. She followed the advice of the attending nutritionist at the Anlene booth to watch her diet, get some exercise, and drink Anlene as a nutrition supplement.

Lene and Mary Ann are just two of the over 1 million Filipinos who have benefitted from the Anlene Bone Health Check campaign. Started in 1999, the nationwide caravan has remarkably helped propagate information on the debilitating silent disease. The caravan provides free bone scanning and assessment, and useful pointers on how to address the onset of osteoporosis.

Osteoporosis occurs when the bone mass decreases quickly more than the body can replace it, leading to a net loss of bone strength. As a result, a slight bump or fall can result to fracture. It affects all bones in the body but fractures occur mostly in the spine, hips, and wrist. Broken bones bring severe pain, and both hip and spine fractures were found out to be associated with a higher risk of death – 20 percent of those who suffer hip fracture die within six months after the fracture.

Proper exercise, keeping a healthy lifestyle and regular intake of calcium-rich milk such as Anlene can help prevent osteoporosis. Anlene is the only milk that is clinically proven to reduce bone breakdown within four weeks.

“My condition has improved with the help of Anlene,” shares Mary Ann. “When I had another bone scan assessment last December, I found out that from high risk, I am now down to moderate risk. I can now take long walks and I no longer feel the pain. My target is to further reduce my condition to low risk, of course with the help of Anlene.”

Lene, though her condition remains stable, vows not to put her health at further risk. Aside from taking Anlene, she also gets involve in physical activities such as aerobics and badminton.

“I got scared when I found out I was under the moderate risk category. But with proper diet, the right exercise and regular intake of Anlene, I have stronger bones now,” says Lene.

The Anlene Bone Health Check continues to reach to countless Filipinos all over the country. For 2012, the project is aimed at scanning another 1 million Filipinos, with a total investment amounting to P50 million to roll out the campaign on osteoporosis awareness. The activities are held in various barangays and malls so that more people can have easy access to free bone scanning and assessment. The progam also scans people across Asia, Australia and the Middle East. It is run in partnership with GE Healthcare, a world leader in medical imaging technology. Dinna Chan Vasquez

Top

(Published in the Manila Standard Today newspaper on /2012/february/13.)

Original post:
Monday February 13 2012